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A bstract. Recently a new linker -  hydrazinonicotinate 
(HYNIC) -  was introduced for labelling of  proteins and 
peptides with technetium-99m. HYNIC and other linkers 
have been used for labelling of human non-specific poly­
clonal immunoglobulin G (hlçG) with 99mTc for the de- 
tection of  infections. In this study we compared the tis­
sue distribution of three different 99mTc-hIgG prepara­
tions in groups of five Wistar rats with a focal intramus­
cular infection with Staphylococcus aureus. We com ­
pared 99mTc-H Y N IC -hlgG  with "™Tc-hIgG labelled via 
the so-called Schwarz method (reduction of  disulphide 
bonds) and with the 99mTc-labelled commercially avail­
able Technescan-HIG. Unlike the HYNIC linker, in the 
two other labelling methods free sulph-hydryl groups are 
involved in the binding of  99mTc. High-performance liq­
uid chromatography analysis o f  the labelled preparations 
and of plasma samples revealed aggregate or polymer 
formation in all three agents; this was least pronounced 
in the product labelled by means of  the Schwarz method. 
The tested preparations did not show signs of  degrada­
tion in vitro. The difference in linker chemistry was re­
flected in the tissue distribution. Thus the biodistribution 
of  "mTc-HYNIC-hlgG was significantly different from 
the distribution of the two other preparations: abscess 
( 1.4%±0.2%ID/g), muscle, liver, spleen, plasma, lung, 
bone marrow, and small intestine concentrations were 
higher at 24 h p.i.; kidney uptake ( 1.19% ±0.08% ID/g) 
was significantly lower. The abscess-to-plasma and the 
abscess-to-muscle ratios (0.5 and 11, respectively), how­
ever, were in the same range for the three preparations 
tested. Quantitative analysis o f  the scintigraphs revealed 
that the total body clearance of  99mTc-H Y N IC-hIgG  was 
significantly slower than for the other agents. The ab­
scess uptake of  99mTc-H YN IC-hIgG  as a percentage of 
the remaining body activity was significantly higher. 
Based on its high abscess uptake, its low uptake in the 
kidneys and the high percentage of its abscess uptake in
Correspondence to: R.A.M.J. Claessens
relation to the remaining body activity, we conclude the 
99mTc-HYNIC-hIgG seems superior to the two othe 
preparations tested for the detection of infections.
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Introduction
Ind iu m -11 1 labelled human non-specific polyclonal im 
munoglobulin G ( MIIn-hIgG) has been proposed for tht 
detection of  inflammatory and infectious lesions [I] 
This agent has proved to be clinically useful in a variet' 
of  infectious diseases and is often superior to conven 
tional agents like labelled leucocytes and gallium-67 ci 
träte [2-7]. Despite the positive characteristics of 11'In 
hlgG, the use of  11'In has a few inherent disadvantages 
11 'In is expensive, not always available and causes a rel 
atively high radiation burden to patients, and its gammi 
radiation is suboptimal for scintigraphy. Technetium 
99m would be a more attractive alternative. However 
\ our first experiences with 99mTc-hIgG (using 2-imino 
thiolane derivatized hlgG) have been inferior as com 
pared with ' " I n - h lg G  |8].
Recently, Abrams et al. introduced a new method fo 
labelling of proteins with 99mTc [9, 10]. Their stud;
showed that 99mTc-hIgG labelled via hydrazinicotinati 
(HYNIC) performs similarly to " ' I n - h lg G  in detecting 
infections in rats. To evaluate the new agent, we com 
pared the tissue distribution and the uptake in in l ection 
in rats o f  99mTc-H Y N IC -hIgG  and " ' ”Tc-hIgG labellec 
with technetium-99m according to a modification ol th< 
so-called Schwarz method [11]. In addition, we include( 
in this comparative study for reference purposes 99mTc 
hlgG prepared by reconstitution of a commercially avail
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-ible fcchnescan-HIG kit (Mallinckrodt Medical, Petten, 
T|ie Netherlands).
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V/C-IgG. Succinimidyl 6-hydrazinopyridine-3-carboxyl- 
chloride was synthesized as described by Abrams et al. 
>me minor modifications in the purification and final de- 
of the /V-BOC-protected precursor. Briefly, su- 
I 6-BOC-hydrazinopyridine-3-carboxylic acid was puri- 
iromatography on silica gel 60 (230-400 mesh ASTM, 
Darmstadt, Germany) using ethyl acetate as an eluent, 
was concentrated to dryness; the residue was recrystal- 
l 20% ethyl acetate in hexane. Succinimidyl 6-hydra- 
ne-3-carboxylate hydrochloride was prepared as fol- 
mg of succinimidyl 6-BOC-hydrazinopyridine-3-car- 
id was dissolved in 1 ml acetic acid and 2 ml of a satu- 
ion of hydrogen chloride gas in acetic acid was added, 
ng for 1 h, diethyl ether was added until a white precip- 
ormed. The settled precipitate was washed 4 times with 
er and dried under high vacuum. This product was used 
ydrogen-1 nuclear magnetic resonance (NMR) spectros- 
elemental analysis were performed at the Department 
c Chemistry of the University of Nijmegen, 
non-specific polyclonal immunoglobulin G was conju- 
hydrazinopyridine-3-carboxylate (6-hydrazino-3-nicoti- 
llows: Lyophilized hlgG (539 mg; Baxter/Hyland Gam- 
). Lessines, Belgium) was dissolved in 5 ml sterile py- 
water. The solution was dialysed overnight at 4°C 
»sphate-buffered saline (pH=7.4; PBS) to remove low- 
mass additives. The dialysed hlgG solution was filtered 
le 0.22-jJ.m filter (Millipore Millex-GV SLGV 025  BS, 
France) and collected in a sterile vial for injection flu- 
ml of this filtered hlgG solution, 0.25 ml I M  sodium 
arbonate solution (pH=8.2) was added. While stirring, 
s of 10 |jl of a succinimidyl-6-hydrazinopyridine-3-car- 
ydrochloride solution (6 mg/ml in dry dimethyl sulph- 
e added to the alkaline hlcG solution at 3-min intervals 
!gG ratio=2.5). After incubation at room temperature 
the mixture was cooled in an ice bath and 3 ml cold 
mm acetate buffer (pH=5.85) was added. The HYNIC- 
ion was dialysed overnight at 4°C against 0.15 M sodi- 
buffer (pH=5.85). The dialysed HYNIC-hlgG solution 
I over a sterile 0.22-|im filter and collected in a sterile 
ection fluids. The protein concentration, as estimated 
io-Rad protein assay (Bio-Rad laboratories, München, 
was adjusted to 4 mg/ml by adding sterile 0.15 M  sodi- 
buffer (pH=5.85). The number of HYNIC groups per 
ule was determined by measuring the optical density 
nm of the hydrazone (extinction coefficient: 
mol-1-cm"1) resulting from the reaction of protein-con- 
Irazino groups with /?-nitrobenzaldehyde 112]. The HY- 
ated hlgG solution was stored under argon gas at 
portions of 0.5 ml (2 mg).
Hing of HYNIC-hlgG with 99mTc, tricine (W-(tris(hy- 
l)methyl)glycine, Fluka Chemika, Buchs, Switzer- 
ised as an intermediary ligand as described by Larsen 
\  volume of 5 ml of saline was added to a vial contain-
c lyophilized stannous sulphate (I mg) and tricine 
mt) under argon gas. From this vial 50 |il was taken and add­
ed to a vial containing 2 mg HYNIC-hlgG. Then, 1480 MBq 
WmTc-pertechnetate in approximately I ml saline was added. The 
mixture was incubated at room temperature for 15 min. The prod­
uct, 99mTc-HYNIC-hIgG, containing approximately 2 mg hlgG, 
was diluted to 5 ml with saline and used as such, provided that the 
amount of pertechnetate was less than 10%.
t)tJmTc-hIgG labelled according to a modification o f the Schwarz 
method. In 1987, Schwarz and Steinsträsser in an abstract de­
scribed a new approach to labelling of monoclonal antibodies with 
99mTc 11 11. Although the method has not been described in detail 
by these authors, it is referred to in the literature as the Schwarz 
method. A more in-depth treatment of this method is given by 
Mather and Ellison [14]. We used a different reducing agent and a 
different intermediary ligand as compared to the original method. 
To 0.3 ml of the dialysed and filtered hlgG solution (see above), 
60 |il of a freshly prepared dithioerythritol solution (DTE, Sigma 
Chemical Company, St. Louis, Mo.; 2 mg in 2 ml 0.1 M tris buff­
er, pH=9) was added. The mixture was incubated for 20 min at 
room temperature. Contaminants of low molecular mass were re­
moved by gel filtration on a PD-10 column (Pharmacia Biotech 
AB, Uppsala, Sweden) using PBS as eluent. The protein fractions 
were pooled, filtered over a sterile 0.22-|im filter and collected in 
a sterile vial for injection fluids. The protein concentration was 
estimated using the Bio-Rad protein assay. The reduced hlgG so­
lution was stored under argon gas at -20°C  in 1-mg portions. The 
number of free sulph-hydryl groups per molecule of IgG was esti­
mated using Ellman’s reagent (Sigma Chemical Company, St. 
Louis, Mo.) [15].
For labelling of DTE-reduced hlgG with " mTc, tricine was 
used as an intermediary ligand, as described for labelling of HY- 
NIC-hlgG. The radiolabelled product, containing approximately 
I mg hlgG, was purified by gel chromatography on a PD-10 col­
umn with PBS as eluent. The protein fractions were pooled and 
the volume was adjusted to 5 ml with saline.
wm Tc-Tech \ i esc an -HIG. A Technescan HIG labelling vial (Mall­
inckrodt Medical, Petten, The Netherlands), containing 1 mg hlgG 
and 8 }ig stannous tin, was reconstituted with 740 MBq 99ltlTc- 
pertechnetate according to the manufacturer’s instructions. The la­
belled product was diluted to 5 ml with saline and used as such.
Radiochemical purity. The radiochemical purity of the three 
99mTc-IabeIled hlgG preparations was determined by instant thin- 
layer chromatography (ITLC) on Gelman ITLC-SG strips (Gel- 
man Laboratories, Ann Arbor, Mich.) with 0.15 M  sodium acetate 
buffer (pH=6.5) as solvent.
In addition to ITLC, samples of the three 99mTc-hIgG prepara­
tions were analysed by size exclusion high-performance liquid 
chromatography (HPLC) using a PROTEIN PAK 300 SW column 
(7.8 mmx300 mm; Mi 11 ipore-Waters, Milford, Mass.) and PBS as 
mobile phase (flow rate 1.0 ml/min). In size exclusion liquid chro­
matography, molecules are eluted in order of decreasing size. The 
eluate was monitored by measurement of the optical density at 
280 nm (OD280) (Millipore-Waters, Milford, Mass.) and by mea­
surement of the radioactivity (Radiomatic, Tampa, FI.). In addi­
tion, a diluted sample of untreated hlgG from the batch used for 
labelling was analysed by HPLC.
In vitro stability. The in vitro stability of 99mTc-HYNIC-hIgG and 
"m jc -h lg G  labelled according to the Schwarz method was esti­
mated by HPLC analysis of samples of each of the labelled pro­
teins 1:3 diluted in PBS or rat plasma, respectively, and incubated 
at 37°C for 24 h.
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Infection model and tissue distribution study
After ether anaesthesia a calf muscle abscess was induced in 
young, male, randomly bred Wistar rats (body mass 200-220 g) 
with approximately 2x10s colony-forming units of Staphylococ­
cus aureus suspended in 0.1 ml of a 1:1 mixture of autologous 
blood and saline. The animals were randomly divided into groups 
of five. Twenty-four hours after inoculation of S. aureus in the 
muscle, when swelling of the muscle was apparent, 0.2 ml of a so­
lution of one of the three radiopharmaceuticals was injected in the 
tail vein. The protein dose per rat was 10 j.ig; the " niTc dose was 
12 MBq per rat.
To collect tissues, rats were killed with 30 mg intraperitoneally 
injected phénobarbital, followed by cervical dislocation at 2, 8 or 
24 h after injection of the radiopharmaceutical. All three radio­
pharmaceuticals were evaluated in five animals at each time point. 
Samples of bone marrow (taken from the right femur), blood and 
urine were collected. Tissues (infected left calf muscle, right calf 
muscle, liver, spleen, kidney, lung, duodenum, and right femur) 
were dissected, blotted dry and weighed. Blood, collected in a 
heparinized tube, was centrifuged and a plasma sample was taken 
and weighed. Plasma and urine samples taken at 7 h after injec­
tion of 99,11Tc-hlgG were analysed by HPLC, as described above.
The radioactivity in the tissues and samples was measured in a 
shielded well-type gamma counter. To correct for radioactive de­
cay and permit calculation of the uptake of the radiopharmaceuti- 
cals in each organ as a fraction of the administered dose, aliquots 
of the respective doses were counted simultaneously. The mea­
sured activity in tissues and samples was expressed as percentage 
of injected dose per gram.
Scintigraphic imaging
A separate set of rats (three rats per radiopharmaceutical) with the 
same infection as described for the biodistribution study were in­
travenously injected with 12 MBq of one of the three 99mTc-hIgG 
(10 jug hlgG) preparations. Scintigraphic images were obtained 
with a Siemens Orbiter gamma camera connected to a Scintiview 
image processor and an Icon computer system (Siemens Inc., 
Hoffman Estates, 111.). All images were acquired in a 256x256 
matrix. A low-energy general-purpose parallel hole collimator 
was used with a 15% symmetric window around the 140-keV 
99mTc gamma peak. Images were acquired at 5 min and 1, 2, 4, 6, 
12 and 24 h after injection of the respective radiopharmaceutical 
with a preset number of 300 kcounts. The time needed to collect 
300 kcounts was noted. Regions of interest were drawn for heart, 
the infection focus, the normal contralateral calf muscle and the 
whole rat body. The whole-body activity at 5 min post injection 
(p.i.) was set at 100%. During imaging the rats were anaesthetized 
with a mixture of oxygen gas (500 ml/min)/nitrous oxide gas 
(300 ml/min) and halothane.
St at ist I ca I analysis
Mean values are given ± the standard deviations (SD). Signifi­
cance was set at 0.05 (two-sided). Before carrying out the statisti­
cal testing, all measured values were log-transformed in order to 
obtain homoscedasticity (log-normal distribution). On these log- 
transformed data from samples taken at 24 h p.i. a one-way AN­
OVA test was performed. In order to evaluate the significance of 
the differences between the three 99mTc-labelled hlgG prepara­
tions, Bonferroni-corrected P values were calculated for each pair 
of radiopharmaceuticals in the study.
Fig. 1. OD:s() profile from HPLC analysis of untreated hlgG (Bax 
ter/Hyland) (A) and radioactivity profiles from HPLC analysis o 
three 99mTc-labelled hlgG preparations immediately after label 
ling: HYNIC-hlgG (B), Schwarz-hlgG (C) and Technescan HIC 
(D). AU. Absorbance units; cps, counts per second
Fig. 2A, B. Radioactivity profiles from HPLC analysis of tw 
"mTc-labelled hlgG preparations after incubation with rat plasm 
at 37°C for 24 h. A HYNIC-hlgG; B Schwarz-hlgG
Results
Conjugation ratio, radiochemical purity 
and in vitro stability
CJ(Jn'Tc-HYNIC-hlgG. Synthesis of  succinimidyl 6-hydr; 
zinopyridine-3-carboxylate hydrochloride: yield: 50 rr 
(61% for the deprotection step). 'H -N M R  5: 2.88 (s,
H), 7.01 (d, 1 H), 8.21 (dd, 1 H), 8.86 (d, 1 H). Analysi 
calculated for C I()H, ,C1N40 4: C, 41.87%; H, 3.87%; I 
19.53%. Found: C, 40.19%; H, 3.92%; N, 18.19%.
The average number of HYNIC groups per hlgG me 
ecule was 2.4. ITLC analysis of the reaction product a 
ter labelling of HYNIC-hlgG with " mTc demonstrated
radiochemical purity of  higher than 98%. Figure 1 
shows the O D 28() profile for unprocessed hlgG from tl
same batch as was used fo r  the labelling procedures  
HYNIC-hlgG and Schwarz-hlgG. The radioactivity pr 
file o f  HPLC analysis o f  the freshly labelled 99mTc-H
European Journal o f  Nuclear Medicine Vol. 23, No. 4, April 19
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time (min) time (min)
Fig. 3 adioactivity profiles from HPLC analysis of plasma sam­
ples i ‘n at 7 h after i.v. injection of 99mTc-HYNIC-hIgG (A), 
wnfjV hwarz-hlgG (B) and 99mTc-Technescan HIG (C)
Fig. 4. Radioactivity profiles from HPLC analysis of urine sam­
ples taken at 7 h after i.v. injection of 99mTc-HYNIC-hIgG (A), 
"mTc-Schwarz-hlgG (B) and 99mTc-Technescan HIG (C)
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üG is shown in Fig. IB. Figure 2A presents the 
tivity profile o f  99mTc-H YN IC-IgG  after 24-h in- 
II in vitro in rat plasma at 37°C.
IgG (Sclnva 17.). The average number of free 
ydryl groups per hlgG molecule after reduction 
TE was 1.6. ITLC analysis after labelling of 
duced hlgG with 99mTc revealed a labelling effi- 
slightly less than 90%. After purification of the
i product by gel filtration, a radiochemical purity 
: than 98% was found. The radioactivity profile 
C analysis immediately after labelling and purifi- 
s shown in Fig. 1C. Figure 2B presents the radio- 
profile o f  99mTc-hIgG (Schwarz) after 24-h incu- 
n vitro in rat plasma at 37°C.
'chnescan-H/G. The amount of  pertechnetate, as 
ned by ITLC, was 3%. Figure ID shows a radio- 
nofile o f  99mTc-Technescan-HIG immediately af- 
ling.
itro stability testing of 99mTc-H Y N IC -hlgG  and 
chwarz-hlgG in rat plasma (Fig. 2) showed for- 
of only small amounts of  degradation products of 
lecular mass. 99mTc-H YN IC-hIgG  showed more 
r or aggregate formation after incubation in rat 
m vitro than did 99mTc-Schwarz-hIgG.
Fig. 5. Concentration of three 9y,nTc-labelled hlgG preparations 
versus time in: abscess (A), muscle (B), plasma (C), and kidney 
(D). Abscess-to-plasma ratio versus time is shown in E and ab- 
scess-to-muscle ratio versus time in F. Experiments were per­
formed in male Wistar rats (five rats per time point)
MJU analysis o f  plasma and urine samples
figure 3 presents the HPLC radioactivity profiles for 
fema samples taken at 7 h after injection of  each o f  the 
three mTc-hIgG preparations. HPLC analysis shows an 
appreciable amount of polymer or aggregate formation
lnr HYNIC-hlgG (Fis*. 3A). As in the freshly labelled
preparations (Fig. 1 ), Schwarz-hlgG has less polymer 
formation than Technescan-HIG, possibly related to the 
difference in the number of free sulph-hydryl groups in 
these two agents. Figure 4 presents the HPLC radioactiv­
ity profiles for urine samples taken at 7 h after injection 
of each of the three 99mTc-hIgG preparations. The three 
profiles show a similar pattern in agreement with urinary
time p.i. (hr) time p.i. (hr)
o>Q
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Table 1. Biodistribution of three 99mTc-la- 
belled hlgG preparations (percentage of in­
jected dose per gram ±SD) in male Wistar 
rats (five rats per time point)
Liver Bone
marrow
2 h p.i.
HYNIC 1.2±0.1 0.8±0.2
Schwarz 0.64±.07 0.49±.07
HIG 1.0±0.1 0.8±0.2
S h p.i.
HYNIC 1.23±0.09 0.57±.04
Schwarz 0.53±0.05 0.34±.09
HIG 0.76±0.05 0.56±.08
24 h p.i.
HYNIC 0.83±0.06 0.45±.02
Schwarz 0.29±0.04 0.17±.02
HIG 0.45±0.05 0.29±.03
Bone Lung Spleen Small
intestin
0 .2 4 ± .0 3 1.2±0.1 1.0 ± 0 .1 0.39+.C
0 .2 9 ± .0 5 0 .8 ± 0 .1 0 .6 4 ± .0 6 0.42+.C
0 .2 5 ± .0 6 0 .9±0 .1 0 .8 5 ± .0 8 0.5+0.1
0 .1 8± .03 1.01 ± .07 0 .8 9 ± .0 6 0.42+.C
0 . 14±.02 0 .4 5 ± .0 4 0 .3 8 ± .0 7 0.24+.C
0 . 15±.02 0 .5 8 ± .0 2 0.61 ± .0 4 0.27+.C
0 . 13±.02 0 .7 0 ± .0 6 0 .8 6 ± .0 7 0.28+.C
0 . 12±.01 0 .2 3 ± .0 3 0 .2 6 ± .0 2 0.13+.C
0 .08± .01 0 .3 2 ± .0 6 0 .3 8 ± .0 6 0.15+.C
Table 2. Bonferroni-corrected P values for the paired comparison 
of the biodistribution at 24 h p.i. of the three 99mTc-labelled hlgG 
preparations in various tissues in male Wistar rats (five rats per 
time point)
HYNIC/
Schwarz
HYNIC/
HIG
Schwarz/
HIG
Plasma P< 0.01 P<0.()1 NS
Abscess P<0.01 P<0.01 NS
Muscle P< 0.01 P< 0.01 NS
Kidney /><(). 01 PcO.Ol NS
Liver P<0.()1 PcO.Ol jP<0.01
Spleen P< 0.01 P<0.01 PcO.Ol
Lung PcO.O1 P< 0.01 P< 0.05
Bone marrow ƒ><(). 01 PcO.Ol PcO.Ol
Significance: P<0.()5; NS, non-significant
excretion of  99mTc-labelled species of  low molecular 
mass.
Biodistribution
Figure 5 shows the radioactivity concentration in abscess 
(5A), muscle (5B), plasma (5C), and kidney (5D) for 
each of  the three 99mTc-hIgG preparations at three time 
points after injection. In contrast to the abscess uptake of 
Schwarz-hlgG and Technescan-HIG, the abscess uptake 
of  99mTc-H Y N IC-hIgG  increases over time (Fig. 5A).
Figure 5E shows the abscess/plasma activity ratios an 
Fig. 5F presents the abscess/muscle activity ratios fc 
the three agents under study at 2, 8 and 24 h after injec 
tion. Despite the differences in the tissue distribution 
the ratios shown in Figs 5E and 5F are similar for tl' 
three agents tested. Table 1 presents the distribution dal 
for the three 99mTc-hIgG preparations at three tin* 
points after injection for tissues not shown in Fig. 5. Tï 
difference in the coordination chemistry of  the 99mTc-l; 
belled proteins in this study is reflected in the tissue di: 
tribution results (Fig. 5, Table 1). 99mTc-HYNIC-hIg' 
behaves in a significantly different way from the othi 
preparations (see Fig. 5 and Tables 1 and 2). At 24 h p. 
the 99mTc uptake in abscess, muscle, plasma, live 
spleen, lung, bone marrow and small intestine obtains 
with 99mTc-H Y N IC-hIgG  is significantly higher the 
that obtained with the other two agents. In contrast, tl 
kidney uptake of  99mT c-H Y N IC -hIgG  is significant 
lower than that o f  the other preparations (see Fig. 5D).
Table 2 presents Bonferroni-corrected P values f 
the pairwise comparison of  the activity uptake at 24 
p.i. in plasma and several tissues o f  the three 99mTc-hIg 
preparations under study.
Scintigraphy
Figure 6 shows scintigraphic images for groups of thr 
rats at 12 h after injection for each of  the three " mTc-l 
belled hlgG preparations. In all rats the infectious fc
Fig. 6. Total body scintigraphy of 
groups of three Wistar rats with an 
S. aureus infection of the left calf
muscle at 12 h after i.v. injection
of 99mTc-HYNIC-hIgG (A), 99mTc- 
Schwarz-hlgG (B) and " mTc- 
Technescan HIG (C)
C
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arly visible. The high renal uptake with Schwarz- 
ind Technescan-HIG is clearly visible (Fig. 6B, 
contrast, the kidney uptake with 99mTc-HYNIC- 
s remarkably low. The slow blood clearance of 
lYNIC-hlgG is reflected in the high activity in 
rt (Fig. 6A).
ire 7A shows the total body retention of radioac- 
ver time as a percentage of the activity at 5 min 
jection for each of the three 99mTc-labelled hlgG 
tions as determined by scintigraphy. The total 
etention of 99mTc-HYNIC-hIgG is significantly 
than that of the other preparations from 4 h p.i. 
s. Figure 7B shows the abscess/total body activi- 
over time for each of the three labelled hlgG 
tions. It is interesting to note that, despite the 
abscess-to-plasma and abscess-to-muscle ratios 
three 99mTc-hIgG preparations (Fig. 5E, F), the 
uptake of 99mTc-HYNIC-hIgG as a percentage 
emaining total body activity is significantly high- 
the percentage for the other two agents (Fig. 7B). 
)nly the absolute value of the uptake in infectious 
l)9mTc-HYNIC-hIgG is significantly higher than 
ess uptake of the other two agents, but also the 
ion of the remaining body activity that is retained 
'\scess is higher for 99mTc-HYNIC-hIgG.
Disci sion
The a i i of this study was to evaluate the potential of the 
newI> developed 99mTc-labelled HYNIC derivatized 
>r the detection of infections in comparison with 
two other 99mTc-hIgG preparations. In addition to HY- 
MC we introduced another commonly used linker 
Wph-iiydryl group generated using the Schwarz meth­
od) into hlgG of the same source (Baxter/Hyland). We 
Reeled this brand of hlsG  because it save the best re-
a comparative study with four brands of hlgG (Bax­
ter/Hyland, CLB, Miles, and Sandoz) and HYNIC as 
linker (E. Koenders, unpublished results). For compara­
tive reasons we included Technescan-HIG from Mall­
inckrodt Medical, which is commercially available for 
the detection of inflammatory lesions. In the latter agent 
free sulph-hydryl groups on AM-imino-4-mercaptobuty- 
lene side chains are introduced by reaction of hlgG with 
iminothiolane.
In our first experiments with HYNIC-hlgG we used 
glucoheptonate as intermediary ligand according to 
Abrams et al. [9]. Glucoheptonate, however, appeared 
suboptimal: it took many hours to obtain >80% labelling 
efficiency and in its presence the amount of stannous tin 
was rather critical: the greater the amount of tin, the 
slower the labelling reaction. The use of tricine as pro­
posed by Larsen et al. [13] gave better labelling results: 
>95% labelling efficiency within less than 20 min under 
otherwise similar conditions.
The HPLC radioactivity profiles of the three " mTc- 
labelled hlgG preparations (Fig. 1B-D) indicate that all 
99mTc-labelled hlgG preparations contained some aggre­
gates or polymers. The least polymeric contamination 
was observed for the so-called Schwarz hlgG (Fig. 1C). 
Based on HPLC analysis of each individual step in the 
labelling process of hlgG, we conclude that aggregate or 
polymer formation is partly caused by the mere handling 
of the hlgG, i.e. keeping it for some time at elevated pH, 
with overnight dialysis. The major part of polymeric 
contamination, however, was formed as a result of the 
chelating agent used. Two of the three hlgG preparations 
in this study use free sulph-hydryl groups to bind tech­
netium. Free sulph-hydryl groups are known to form di­
sulphide bonds spontaneously, especially at pH=7.8 and 
above. This reaction is catalysed by traces of metal ions. 
Therefore, to stabilize solutions of Fab' fragments, small 
amounts of EDTA are added. To our preparations no 
EDTA was added. As stated above, the Schwarz-hlgG 
contained least polymeric contamination. An explana­
tion of this phenomenon may be provided by the fact 
that in Schwarz-hlgG the average number of free sulph- 
hydryl groups per molecule of protein is 1.6, whereas in 
iminothiolane-modified hlgG (Technescan-HIG) the av­
erage number of free sulph-hydryl groups is probably 
higher (this could not be determined with Ellman’s re­
agent for Technescan-HIG because of the presence of 
stannous tin in the kit formulation). Moreover, in 
Schwarz-hlgG pairs of sulph-hydryl groups are in close 
proximity. Therefore, upon reoxidation in Schwarz-hlgG, 
formation of intramolecular disulphide bridges will 
probably prevail over intermolecular bond formation.
The HYNIC-modified hlgG also contained an appre­
ciable amount of polymers or aggregates. A possible ex­
planation for this is provided by the work of King et al. 
[12]. They showed that at concentrations as low as 
10 Ii M  acyl hydrazide-modified proteins react with aryl 
aldehyde-modified proteins, forming polymeric protein
Sl1'^ in terms of abscess uptake and tissue distribution in species. Phenyl hydrazines are known to form phenyl
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hydrazones after reaction with carbonyl functions in 
sugar molecules. IgGs are glycoproteins and contain 
sugar residues. The hydrazino groups might react with 
sugar molecules in the same or another protein mole­
cule, thus forming cross-links and polymeric protein 
species. This possible explanation for the observation, il­
lustrated by Figs. IB, 2A and 3A, is supported by the 
fact that we found no or almost no polymer formation 
after modification of albumin (which does not contain 
sugar moieties) with HYNIC. The recent work of Verb- 
eke and colleagues confirms the absence of polymeric 
species in the preparation formed after labelling o f  HY- 
NIC-HSA with 99mTc [16].
HPLC analysis o f  plasma samples shows even less 
formation of degradation products o f  low molecular 
mass than HPLC analysis after incubation in rat plasma 
in vitro. Low-molecular-mass metabolites are rapidly ex­
creted through the kidneys, as confirmed by HPLC anal­
ysis of urine samples (see Fig. 4).
The low kidney uptake of  99mTc-HYNIC-hIgG is of 
importance with respect to the detection of  intra-abdom­
inal and retroperitoneal infectious foci. The relatively 
high renal uptake of the other two 99mTc-hIgG prepara­
tions is probably related to formation of  small free 
sulph-hydryl-containing metabolites in the two agents 
using sulph-hydryl groups for coordination of techne­
tium. This may be the result of  protein catabolism or 
transchelation of  technetium to cysteine or a cysteine­
like molecule [17]. The second possibility seems more 
likely: it could be demonstrated by means of a double la­
belling experiment with 99mT c /14C-hIgG (with free 
sulph-hydryl groups for binding of technetium) in rats 
that the disappearance rate of 99mTc from plasma was 
faster than the plasma disappearance rate of l4C-hIgG. 
Moreover, in plasma formation of 99mTc-labelled materi­
al of  low molecular mass was observed and a 99mTc-la- 
belled species was found to be retained in the kidneys
[18]. Molecules with free sulph-hydryl groups with or 
without 99mTc are known to be retained in the renal cor­
tex. 14C-dimercaptosuccinic acid (DM SA) and " mTc- 
DM SA are examples of  such agents [19]. Metal- 
lothionein, a metal binding protein in the renal cortex 
with a cysteine content as high as 30%, is the binding 
site for metal ions like cadmium and zinc and probably 
also for mercury (Hg+) ions [20]. Metallothionein is sup­
posed to bind not only metal ions, but also sulph-hydryl- 
containing molecules like l4C -D M SA  [21]. It has actual­
ly been demonstrated that l4C -D M SA  and Hg+ ions 
compete for the same binding site in the renal cortex
[19], After administration of  99mTc-labelled DM SA a 
99mTc-labelled species has been proposed to be retained 
in the renal cortex after partial dissociation of the 99mTc- 
labelled complex [19]. The mechanism for renal binding 
of  99mTc-labelled D M SA could also explain the retention 
in the kidney of  99mTc-labelled cysteine or a cysteine­
like molecule.
Despite the higher abscess uptake of 99mTc-HYNIC- 
hlgG, the abscess-to-plasma and the abscess-to-muscle
ratios are similar for the three agents in this stud 
(Fig. 5E, F), suggesting that the higher uptake of 
HYNIC-hlgG in infections and most tissues is related t 
its slower plasma clearance. The latter might be e,\ 
plained by the relatively high in vivo stability of th 
99mTc-HYNIC-hIgG preparation. The high and over tini 
increasing abscess uptake of  99mTc-HYNIC-hIgG i 
probably not only related to its slow plasma clearanct 
In foci o f  infection 99mTc seems to be released fror 
99mTc-HYNIC-hIgG and retained locally [18]. The ree 
son for this phenomenon is not yet known.
In conclusion: In this comparative study 99mTc-H\ 
NIC-hlgG had the highest abscess uptake, the lowe: 
kidney uptake and the highest proportion o f  the reman­
ing body activity that is retained in the abscess. In viv 
in rats, 99mTc-HYNIC-hIgG behaved significantly diffei 
ently from the other two 99mTc-hIgG preparations use 
in this study. This is a reflection of  the differences in th 
chelating chemistries in these agents. Based on our rt 
suits 99mTc-HYNIC-hIgG seems the superior agent fc 
detection of infectious foci as compared to two oth( 
99mTc-hIgG preparations.
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